AmgenvsRegeneron Pharmaceuticals

AMGN and REGN stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$462.32

Value $249B

-0.72%
AMGN's page

REGN

Regeneron Pharmaceuticals, Inc.

$952.40

Value $99.6B

-0.32%
REGN's page

Amgen (AMGN) has a market value of $249B and Regeneron Pharmaceuticals (REGN) $99.6B. The P/E is 26.5 for AMGN and 20.7 for REGN. Dividend yield: AMGN 2.15%, REGN 0.39%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$249B

    REGN$99.6B

    AMGN is 2.5 times REGN

  • Revenue, 12 months

    AMGN$38.9B

    REGN$16.9B

    AMGN is 2.3 times REGN

  • Net income, 12 months

    AMGN$9.4B

    REGN$4.8B

    AMGN is 1.9 times REGN

  • Operating margin

    AMGN32.4%

    REGN28.8%

    3.6 points apart

  • ROIC

    AMGN16.2%

    REGN12.2%

    4.0 points apart

  • P/E

    AMGN26.5

    REGN20.7

    AMGN is 1.3 times REGN

  • Dividend yield

    AMGN2.2%

    REGN0.4%

    1.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

Prices are not available right now.

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenREGNRegeneron Pharmaceuticals

Valuation

AMGNREGN
Valuation
Price$462.32$952.40
Market value$249B$99.6B
Enterprise value (EV)$290B$93.0B
P/E26.520.7
P/E, 5-year median23.018.6
P/B17.43.0
EV/EBIT23.019.1
Free cash flow yield3.8%3.8%

Results and growth

AMGNREGN
Results and growth
Revenue, 12 months$38.9B$16.9B
Net income, 12 months$9.4B$4.8B
Free cash flow, 12 months$9.6B$3.8B
Earnings per share, 12 months$17.25$45.30
Revenue growth, year on year10.0%1.0%
Revenue growth a year, past+7.6%over 5 years+11.0%over 5 years
EPS growth a year, past+2.9%over 5 years+6.3%over 5 years

Margins and returns on capital

AMGNREGN
Margins and returns on capital
Gross margin70.9%–
Operating margin32.4%28.8%
Net margin24.1%28.5%
ROIC16.2%12.2%
ROE87.8%15.2%

Balance sheet

AMGNREGN
Balance sheet
Cash$13.2B$9.3B
Total debt$54.0B$2.7B
Net debt / EBITDA2.3-1.2
Interest cover4.8×104.2×

Dividends and buybacks

AMGNREGN
Dividends and buybacks
Dividend yield2.2%0.4%
Dividend per share, 12 months$9.94$3.70
Dividend growth a year, past+8.1%over 5 years–
Buyback yield–3.5%
Shareholder yield2.2%3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or REGN

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Regeneron Pharmaceuticals?

By market value, Amgen ($249B) is about 2.5 times Regeneron Pharmaceuticals ($99.6B), at today's prices.

Which pays the higher dividend, AMGN or REGN?

The dividend yield at today's price is 2.15% for Amgen and 0.39% for Regeneron Pharmaceuticals. Over the last twelve months they paid $9.94 and $3.70 per share.

What is the P/E of AMGN and REGN?

At today's price, the P/E is 26.5 for AMGN and 20.7 for REGN. The median of the last five years was 23.0 and 18.6, which shows where each stands against its own past.

Which has the higher profit margins, Amgen or Regeneron Pharmaceuticals?

Over the last twelve months, the net margin was 24.1% for Amgen and 28.5% for Regeneron Pharmaceuticals, and the operating margin 32.4% and 28.8%. Revenue was $38.9B and $16.9B.

Which is the better investment, Amgen or Regeneron Pharmaceuticals?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.